DCDezhu Chen

Dezhu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dezhu Chen has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Fengguang Kang

    Department of Emergency, ShunDe Hospital of Guangzhou University of Chinese Medicine, Foshan, People’s Republic of China

    2 shared publications
  • Bei Hu

    Department of Emergency Medicine, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    1 shared publication
  • Bo Lv

    Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

    1 shared publication
  • Caidi Gong

    Department of Emergency, ShunDe Hospital of Guangzhou University of Chinese Medicine, Foshan, China

    1 shared publication
  • Cheng Sun

    Department of Critical Care Medicine, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University , Guangzhou

    1 shared publication
  • Chunbo Chen

    Department of Critical Care Medicine, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), China

    1 shared publication

Latest Publications

  • Open Access

    Association between nicotine-dependent patients and delirium in intensive care units: a retrospective cohort study using a large clinical database

    by Mengqing Yang, Zhengxin Hu, Yun Huang, Guohao Zhang, Fengguang Kang, Dezhu Chen

    Although nicotine use is a significant and potentially modifiable risk factor for delirium in ICU patients, evidence on the association between nicotine dependence (ND) and ICU delirium remains limited. This retrospective cohort study used the MIMIC-IV v3.1 database and included adult patients admitted to the ICU for ≥ 24 h with documented delirium assessments. Patients with schizophrenia, dementia, depression, alcohol abuse, or cerebrovascular disease were excluded. Patients were classified into ND and non-ND groups. The primary outcome was ICU delirium incidence; secondary outcomes included in-hospital mortality, ICU mortality, hospital length of stay, and ICU length of stay. Confounders were balanced using 1:1 propensity score matching (PSM). Cox regression and competing risk models were used to assess the association between ND and delirium. Subgroup and sensitivity analyses were performed, and the effects of ICD coding versions and NRT treatment were also evaluated. A total of 24,043 patients were included, with 2,662 (11.07%) in the ND group. After PSM, baseline characteristics were balanced. The ND group had a significantly higher incidence of delirium than the non-ND group (30.8% vs. 27.2%, P = 0.004), with no significant differences in mortality or length of stay. Multivariate Cox and competing risk models confirmed that ND was independently associated with increased ICU delirium risk. Findings remained consistent in PSM and sensitivity analyses. Nicotine dependence significantly increases the risk of ICU delirium. These results highlight the need for targeted risk assessment and intervention strategies in ND patients admitted to the ICU.


  • RIPK3 activation promotes peritoneal dialysis-related peritoneal fibrosis via NLRP3/Caspase-1/IL-1β pathway

    by Zhiyong Xie, Rong Wei, Wenying Zhang, Xiaodong Tang, Hang Chen, Qilan Nie, Xinying Zhang, Yilin Chen, Zhuohan Li, Ziqing Tan, et al.


  • Global health implications of urticaria burden (1990–2021): a comprehensive analysis of trends across nations and regions

    by Zhaoyan Zhao, Yun Huang, Dezhu Chen, Youfa Wang

    Introduction: Urticaria is a widespread dermatological disorder that substantially affects patients’ quality of life. Current data on its worldwide impact are crucial for healthcare planning and resource distribution. By analyzing the Global Burden of Disease (GBD) Study 2021, we evaluated the burden of urticaria across global, regional, and national levels.Material and methods: A comprehensive analysis was performed using data from the GBD 2021 study. Key metrics included prevalence, incidence, and age-standardized rates, all calculated per 100,000 people. The results were analyzed across demographic factors including age groups, gender, and geographical locations.Results: From 1990 to 2021, global urticaria metrics demonstrated relative stability, with female patients consistently reporting higher rates. During this period, the number of prevalent cases increased from approximately 48 million to 66.5 million, with the age-standardized prevalence rate (ASPR) showing a slight rise from 866 to 868 per 100,000 population. The number of incident cases increased from about 85 million to 117 million, while the age-standardized incidence rate (ASIR) showed a marginal increase from 1,529 to 1,534 per 100,000. The global age-standardized DALY rate reached 52.1 per 100,000 in 2021, ranging from 27.7 in Portugal to 88.4 in Nepal. The disease burden was most pronounced in low-middle SDI regions and lowest in high SDI areas. At the country level, Nepal recorded the highest burden across all metrics, while Portugal showed the lowest.Conclusions: Our analysis spanning three decades revealed that while the overall global burden of urticaria has remained relatively stable, there has been a modest upward trend in both prevalence and incidence. Notable disparities have emerged, with disproportionate impacts observed across different populations: females experience higher rates of the condition, and low-middle SDI regions shoulder a greater disease burden. These patterns highlight the importance of developing focused healthcare strategies and optimizing resource distribution, particularly in heavily affected regions. Given the inherent limitations of GBD data, these findings should be interpreted with appropriate caution.


  • Open Access

    Atrial fibrillation ablation compared to pacemaker therapy in patients with tachycardia–bradycardia syndrome: A systematic review and updated meta-analysis

    by Lijun Su, Xiaoqi Wang, Fengguang Kang, Caidi Gong, Dezhu Chen

    Background: Tachycardia–bradycardia syndrome (TBS) is a subtype of sick sinus syndrome characterized by prolonged sinus pause (≥3 s) following termination of tachyarrhythmias, primarily atrial fibrillation (AF). There is controversy regarding whether the long-term prognosis of AF ablation is superior to pacemaker implantation. This study aimed to compare the effects of AF ablation and pacemaker therapy in patients with TBS. Methods: We conducted a comprehensive search of electronic databases, including PubMed, Cochrane, EmBase, Web of Science, and Chinese BioMedical, up until December 1, 2023. We included studies that reported the effects of AF ablation vs pacemaker therapy in patients with TBS. From this search, we identified 5 studies comprising 843 participants with TBS who underwent catheter AF ablation or pacemaker therapy. Results: Our meta-analysis revealed that AF ablation and pacemaker therapy had similar effects on cardiovascular death (odds ratio [OR] = 0.62 and 95% confidence interval [CI]: 0.14–2.65), procedural complications (OR = 1.53 and 95% CI: 0.67–3.48), and cardiovascular rehospitalization (OR = 0.57 and 95% CI: 0.26–1.22). However, AF ablation provided greater benefits than pacemaker therapy in terms of all-cause mortality (OR = 0.37 and 95% CI: 0.17–0.82), thromboembolism (OR = 0.25 and 95% CI: 0.12–0.49), stroke (OR = 0.28 and 95% CI: 0.13–0.57), heart failure (OR = 0.27 and 95% CI: 0.13–0.56), freedom from AF (OR = 23.32 and 95% CI: 7.46–72.92), and prevention of progression to persistent AF (OR = 0.12 and 95% CI: 0.06–0.24). Furthermore, AF ablation resulted in a reduced need for antiarrhythmic agents (OR = 0.21 and 95% CI: 0.08–0.59). Conclusion: AF ablation can effectively reduce the risk of all-cause mortality, thromboembolism, stroke, heart failure, and progression to persistent AF in patients with TBS. Additionally, it may eliminate the need for further pacemaker therapy in most cases after ablation. Therefore, AF ablation is considered superior to pacemaker therapy in the management of patients with TBS.


  • Simo decoction versus domperidone suspension for post-pyloric spiral nasoenteric tube placement: A multicenter, randomized, non-inferiority trial

    by Yingkai Xiao, Zhimei He, Yi Long, Weisheng Chen, Dezhu Chen, Ruibin Chi, Heng Ye, Xi Deng, Bo Lv, Cheng Sun, et al.